Cumulative probability of visiting an HIV clinic.

<p>Results are overall among a) all HIV seropositive persons (n = 152) and b) those not already on ART at baseline (n = 120). After month one, for those on ART, follow-up was discontinued. The cumulative probability of visiting an HIV clinic by 3 months was 88.5% overall and 85.3% among those not already on ART at baseline (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051620#pone-0051620-g001" target="_blank">Figure 1a and 1b</a>, respectively).</p

Cumulative probability of ART initiation, among HIV seropositive persons with a CD4 count <250 cells/µL and not on ART at baseline.

<p>Results are shown for the 21 HIV seropositive individuals who had a baseline CD4 count <250 cells/µL and were eligible for ART by Ugandan guidelines but not taking 7 ART at baseline. The cumulative probability of ART initiation by 3 months among those with CD4 count <250 cells/µL and not on ART at baseline was 71.4%.</p

Follow-up.

*<p>Cumulative % is estimated by the Kaplan-Meier method.</p

Home-based HIV counseling and testing in southwestern Uganda.

<p>HBCT = home-based HIV counseling and testing.</p

Cumulative probability of male circumcision, among HIV seronegative men with multiple partners or a known HIV seropositive partner.

<p>Results are shown for the 123 HIV seronegative men with >1 sexual partner (>2 if polygamous) or a known HIV seropositive partner who were referred for medical male circumcision. The cumulative probability of male circumcision by 3 months was 62.0%.</p

Population characteristics.

*<p>Married monogamous represents civil as well as religious marriages.</p

Study Schema.

<p>Study Schema.</p

Baseline Characteristics of Enrolled HIV-1 Serodiscordant Couples (N = 4758).

<p>*Any contraceptive use includes: oral, injectable and implantable contraceptives, intrauterine device, hysterectomy or bilateral tubal ligation.</p><p>**Data on sexually transmitted infections available from a subset of participants.</p

Study Inclusion and Exclusion Criteria.

<p>Study Inclusion and Exclusion Criteria.</p

Study Site Laboratory Assays.

<p>*Jinja & Kampala used Vironostika 3^rd gen until March 2010.</p><p>**Tororo & Mbale used Roche C111 until Sept 2010. </p><p>Kabwohe used ^†Immutrep RPR, and</p>‡<p>Determine Syphilis TP until May 2010.</p